Understand what your organ health supplements results really mean
See your biomarkers in context with a comprehensive panel.
- CLIA-certified labs
- HIPAA compliant
- Personalized health protocol
Quick answer: DPA (docosapentaenoic acid) is the third major marine omega-3 fatty acid, found alongside EPA and DHA in fatty fish and fish oil. It is present in modest amounts in most omega-3 supplements and has been studied for roles in inflammation, platelet function, and conversion to other fatty acids. DPA is less researched than EPA or DHA but shares some of their biological activities and may act as a reservoir that the body converts to both.
What is DPA, and why does it matter?
When most people think about omega-3 fatty acids, they think about EPA and DHA. These two get the most attention in research, the most space on supplement labels, and the most discussion in clinical guidelines. But there is a third marine omega-3 that sits quietly between them in the metabolic pathway: docosapentaenoic acid, or DPA.
DPA (specifically n-3 DPA, also written as 22:5n-3) is present in the same foods that provide EPA and DHA — fatty fish, fish oil, krill oil, and some algal oils. It tends to appear in smaller concentrations than its better-studied counterparts, which is partly why it has received less research attention. That is beginning to change. Studies have started examining DPA's independent biological activities, and its role as a metabolic intermediate between EPA and DHA is becoming better understood.
Understanding DPA matters for anyone who reads omega-3 labels, follows fatty acid research, or is trying to interpret the growing body of work on omega-3 status and cardiovascular health.
The three marine omega-3s: EPA, DPA, and DHA
EPA (eicosapentaenoic acid, 20:5n-3)
EPA is a 20-carbon omega-3 fatty acid that serves as a direct precursor to a class of anti-inflammatory signaling molecules called eicosanoids, including prostaglandins, thromboxanes, and leukotrienes of the 3-series. These tend to be less pro-inflammatory than the equivalent molecules derived from arachidonic acid (an omega-6 fatty acid). EPA is also involved in platelet aggregation, vascular tone, and triglyceride regulation. It is the omega-3 most directly implicated in the cardiovascular benefits observed in high-dose fish oil trials like REDUCE-IT.
DHA (docosahexaenoic acid, 22:6n-3)
DHA is a 22-carbon omega-3 that accumulates preferentially in neural tissue and the retina. It is a structural component of cell membranes, particularly in the brain and eyes, where it influences membrane fluidity and receptor function. DHA is the dominant omega-3 in breast milk and is essential for fetal brain development. It also contributes to triglyceride lowering and anti-inflammatory signaling, though through different mechanisms than EPA.
DPA (docosapentaenoic acid, 22:5n-3)
DPA sits between EPA and DHA in carbon chain length and in the metabolic pathway. EPA is elongated to form DPA, which can then be further desaturated to form DHA. This places DPA in a bridging position: it is downstream of EPA and upstream of DHA. DPA also retrogrades to EPA when needed, meaning it may function as a circulating reserve of both parent fatty acids. Research published in the European Journal of Nutrition has shown that DPA supplementation raises plasma EPA concentrations, consistent with this bidirectional conversion capacity.
Where DPA is found
Fatty fish and marine sources
DPA is present in the same marine foods that supply EPA and DHA. Salmon, mackerel, sardines, herring, and tuna all contain measurable DPA, though in lower concentrations than EPA or DHA. Most analyses find DPA at roughly 10–20% of the EPA content in a given fish or fish oil product. Seal oil is an unusually rich DPA source, containing a higher DPA-to-EPA ratio than most fish oils, which has made it useful in research settings.
Fish oil and krill oil supplements
Standard fish oil capsules typically contain a mixture of EPA, DHA, and DPA. Because DPA concentrations are lower in raw fish oil and not typically highlighted in marketing, most supplement labels show only EPA and DHA totals. Consumers who look for DPA specifically will generally need to review certificates of analysis or contact manufacturers for detailed fatty acid profiles.
Red meat and dairy
DPA is also present in ruminant animal products — beef, lamb, and dairy. These provide the n-3 form of DPA (22:5n-3), the same metabolically active form found in marine sources. This is distinct from ALA (alpha-linolenic acid), the plant-derived omega-3 found in flaxseed and walnuts, which must undergo a separate, inefficient conversion pathway. Ruminant DPA is bioavailable and contributes meaningfully to DPA status in populations that consume red meat.
What DPA does in the body
Metabolic conversion to EPA and DHA
The most established function of DPA is as a metabolic intermediate. When the body requires EPA or DHA, DPA serves as a reserve substrate. Research suggests this conversion is physiologically significant — supplemental DPA raises circulating EPA levels, and the body preferentially incorporates DPA into membrane phospholipids from which it can be mobilized. This buffering function may be important during periods of low dietary omega-3 intake.
Platelet aggregation and thrombosis
DPA has been studied for effects on platelet function, which is relevant to cardiovascular health. In vitro studies have found that DPA inhibits platelet aggregation, a mechanism shared with EPA and DHA. Some research has suggested DPA may have comparable or greater antiplatelet activity than EPA on a molar basis, though most of this work has been conducted in cell or animal models. Human intervention data specific to DPA are limited.
Inflammation and lipid mediators
DPA gives rise to specialized pro-resolving mediators (SPMs) including a class called protectins and resolvins. SPMs are bioactive lipids that actively promote the resolution of inflammation rather than simply suppressing inflammatory initiation. Research from Charles Serhan's laboratory at Harvard has identified DPA-derived resolvins (RvDn-6 DPA series) that exhibit potent anti-inflammatory activity in preclinical models. Whether these translate to clinically meaningful effects in humans requires further investigation.
Vascular and endothelial function
DPA has been associated with effects on endothelial cell function, including promotion of endothelial cell migration and repair. Some observational studies have found inverse associations between plasma DPA and cardiovascular events, though distinguishing DPA's independent contribution from that of EPA and DHA in habitual fish consumers is methodologically difficult, as these fatty acids co-occur in the same foods and tend to be correlated in plasma.
Test 100+ biomarkers from home
One blood draw. A full picture of your health, explained in plain language.
Test 100+ biomarkers from home
One blood draw. A full picture of your health, explained in plain language.
DPA levels in the body and how they are measured
DPA status can be assessed through fatty acid profiling of plasma or red blood cell membranes. Red blood cell fatty acid analysis is generally preferred for assessing longer-term status, as red cell membranes reflect approximately three months of intake (similar to the logic behind HbA1c for blood sugar). Plasma fatty acid levels reflect more recent dietary intake.
These tests are not part of standard clinical blood panels. They are available through specialty laboratory testing and are most commonly ordered in research contexts or by clinicians evaluating omega-3 status comprehensively. Interpretation requires context: DPA values should be assessed alongside EPA and DHA rather than in isolation, and results are typically expressed as a percentage of total fatty acids rather than an absolute concentration.
For individuals interested in understanding their omega-3 status more broadly, a comprehensive metabolic panel can provide relevant context on cardiovascular and inflammatory markers. Superpower's Baseline Blood Panel includes lipids and inflammatory markers that complement fatty acid testing.
Should you look for DPA in your omega-3 supplement?
The practical guidance here is nuanced. DPA is present in most fish oil and krill oil products, even when not listed prominently. If you are consuming a high-quality fish oil that specifies EPA and DHA content, DPA is likely present as well.
Whether to specifically seek out high-DPA products — such as seal oil or specialty supplements marketed around DPA content — depends on your goals. The strongest clinical evidence for omega-3 supplementation remains concentrated around EPA and DHA. DPA's independent clinical evidence is more limited, though its biological activity and metabolic role suggest it is not inert. The broader pattern of consuming adequate total marine omega-3s from food and supplementation is more important than optimizing for any single fatty acid within the omega-3 family.
Which biomarkers are worth tracking alongside omega-3 intake?
Because omega-3 fatty acids are primarily studied in the context of cardiovascular and inflammatory health, the following biomarkers provide meaningful context for evaluating your omega-3 status and overall risk profile:
- Triglycerides — High-dose omega-3s are among the most effective dietary interventions for lowering triglycerides
- hs-CRP — systemic inflammation; EPA and DHA are associated with modest reductions
- ApoB — Most accurate measure of atherogenic particle burden; relevant to cardiovascular risk assessment
- HDL cholesterol — Omega-3s may modestly raise HDL in some individuals
This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making changes to your health routine or supplement regimen.
Frequently Asked Questions
References
- Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT, Juliano RA, Jiao L, Granowitz C, Tardif JC, Ballantyne CM, REDUCE-IT Investigators (2019). Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. *The New England journal of medicine*, *380*(1), 11-22. https://doi.org/10.1056/NEJMoa1812792
- Lauritzen L, Brambilla P, Mazzocchi A, Harsløf LB, Ciappolino V, Agostoni C (2016). DHA Effects in Brain Development and Function. *Nutrients*, *8*(1). https://doi.org/10.3390/nu8010006
- Miller E, Kaur G, Larsen A, Loh SP, Linderborg K, Weisinger HS, Turchini GM, Cameron-Smith D, Sinclair AJ (2013). A short-term n-3 DPA supplementation study in humans. *European journal of nutrition*, *52*(3), 895-904. https://doi.org/10.1007/s00394-012-0396-3
- Drouin G, Rioux V, Legrand P (2019). The n-3 docosapentaenoic acid (DPA): A new player in the n-3 long chain polyunsaturated fatty acid family. *Biochimie*, *159*, 36-48. https://doi.org/10.1016/j.biochi.2019.01.022
- Akiba S, Murata T, Kitatani K, Sato T (2000). Involvement of lipoxygenase pathway in docosapentaenoic acid-induced inhibition of platelet aggregation. *Biological & pharmaceutical bulletin*, *23*(11), 1293-7. https://doi.org/10.1248/bpb.23.1293
- Burdge GC, Wootton SA (2002). Conversion of alpha-linolenic acid to eicosapentaenoic, docosapentaenoic and docosahexaenoic acids in young women. *The British journal of nutrition*, *88*(4), 411-20. https://doi.org/10.1079/BJN2002689
